LAIYANG, China, Nov. 3 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced the launch of its new corporate website with the domain address http://www.genesispharmaceuticals.com .
The website features an overview of the Company, its corporate history, current products and recent news. The website includes an investor relations section from which users can download presentations and filings.
"We are very pleased to officially launch our new corporate website. We believe that this new website will provide a quick and easy way for our customers, investors and business partners to access key information about Genesis Pharmaceuticals and communicate directly with us," said Mr. Wubo Cao, Chief Executive Officer of Genesis. " Through frequent and regular updates, we believe our website will be an effective tool that will increase awareness of our Company's products among consumers, enhance contacts with our investors, and raise awareness of our business within the investment community."
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are not
guarantees of future performance and are subject to risks and uncertainties
that could cause the Company's actual results and financial position to
differ materially from those included within the forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including those relating to the Company's ability to introduce, manufacture
and distribute new drugs. Actual results may differ materially from
anticipated or predicted results, and reported results should not be
considered as an indication of future performance. The potential risks and
uncertainties include, among others, the Company's ability to obtain raw
materials needed in manufacturing, the continuing employment of key
employees, the failure risks inherent in testing any new drug, the
possibility that regulatory approvals may be delayed or become unavailable,
patent or licensing concerns that may include litigation, direct
competition from other manufacturers and product obsolescence. More
information about the potential factors that could affect the Company's
business and financial results is included in the Company's filings,
available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
|SOURCE Genesis Pharmaceuticals Enterprises, Inc.|
Copyright©2008 PR Newswire.
All rights reserved